Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
4 DSLR Cameras for Amateurs in 202405.06.2024 - 2Finding Your Motivation: Moves toward a Satisfying Life01.01.1
- 3NASA probe captures stunning photos of Earth and moon on the way to infamous asteroid Apophis28.11.2025
- 4Vote In favor of Your Favored Video Conferencing Administration05.06.2024
- 5'Stranger Things' character guide: The nerds, the newcomers and the rest of the Season 5 cast26.11.2025
- Vote In favor of Your Favored Cereal
- Tesla plans to expand production at German car plant
- From a new flagship space telescope to lunar exploration, global cooperation – and competition – will make 2026 an exciting year for space
- Partake in the Outside: Senior-Accommodating Exercises for 2024
- Novartis eyes more bolt-on acquisitions, CEO says
- Germany raises prospect of military forces to secure Ukraine peace
- Why do people get headaches and migraines? A child neurologist explains the science of head pain and how to treat it
- Birds at a college changed beak shapes during the pandemic. It might be a case of rapid evolution
- The Most Compelling Innovation Advancements Somewhat recently
